New York State Bar Association (NYSBA) Journal Publishes Ron Lanton III Article on Global Healthcare Reform and Life Sciences Strategy

Lanton, Lanton & Sosa Law PLLC is pleased to share that Ron Lanton III’s article, “The Global Healthcare Divorce: How US and EU Reforms Are Reshaping the Structure of Life Sciences Companies,” was published in the Summer 2026 issue of the New York State Bar Association Journal.

The article examines how healthcare reform in the United States and European Union is beginning to affect more than compliance. These changes are also shaping life sciences strategy, company structure, market access, exclusivity, reimbursement planning, and capital decisions.

For healthcare and life sciences companies, the larger takeaway is that regulatory change is becoming a business planning issue. Companies operating across markets need to understand how policy developments may affect contracts, commercialization strategy, investor expectations, and long-term growth.

At Lanton, Lanton & Sosa Law PLLC, we work with healthcare organizations, life sciences companies, pharmacies, physician groups, and health-adjacent businesses on the legal, regulatory, and strategic issues that affect growth in highly regulated markets.

The article begins on page 51 of the Summer 2026 NYSBA Journal seen at https://nysba.org/wp-content/uploads/2026/06/jrnl_summer2026-6-23-26-FINAL-WEB.pdf

Unpacking the Framework: Inside the US-UK Tech Prosperity Deal

While the recent suspension of the US-UK "Tech Prosperity Deal" has dominated the headlines, smart stakeholders know that to navigate the future, you must understand the blueprint. Signed during President Trump’s state visit to the UK in September 2025, this agreement was designed to be a "generational step-change" in the transatlantic special relationship.

Based on the Memorandum of Understanding and the US Embassy’s summary, here are the three core pillars of the deal that every tech and energy leader needs to know.

1. Artificial Intelligence: Aligning Standards & Science

The deal focuses heavily on regulatory alignment to prevent a fragmented AI market.

• Standards & Safety: It establishes a direct partnership between the U.S. Center for AI Standards and Innovation (CAISI) and the UK AI Security Institute (AISI) to harmonize model testing and risk management.

• AI for Science: A flagship program was created to link U.S. agencies (DOE, HHS, NSF) with UK counterparts to accelerate biotechnology breakthroughs, specifically in cancer research and precision medicine.

2. Civil Nuclear Energy: Cutting Red Tape & Russian Dependence

For the energy sector, the deal proposes a radical streamlining of regulatory hurdles.

• Faster Licensing: The agreement targets a timeline of just two years for reactor design reviews and one year for site licensing by aligning the U.S. Nuclear Regulatory Commission and UK Office for Nuclear Regulation.

• Energy Security: It commits the UK to full independence from Russian nuclear fuel by 2028, ensuring a secure, allied supply chain.

3. Quantum Computing: The Race for Standards

Recognizing that Quantum is the next frontier, the deal emphasizes interoperability. It creates a joint benchmarking task force to set shared standards for hardware and algorithms, ensuring that U.S. and UK quantum ecosystems can grow together rather than as competitors.

The "Operative" Clause

Crucially, the MOU includes a provision that the deal only becomes "operative" alongside progress on the broader Economic Prosperity Deal. This legal nuance is exactly why the current trade disputes have halted implementation—a reminder that in international agreements, the fine print always matters.

Call to Action Whether this deal is revived or renegotiated, the regulatory intent of both nations is clear. If your organization operates in AI, nuclear energy, or quantum computing, you need a strategy that anticipates these converging standards. Contact Lanton Strategies today to position your business for the future of transatlantic tech policy.

Policy Alert: What the £31bn Tech Deal Suspension Means for US and UK Innovation

With the Trump administration’s sudden suspension of the £31bn "Tech Prosperity Deal," the future of transatlantic innovation faces immediate and critical uncertainty. As reported, this landmark agreement—intended to bolster cooperation in AI, quantum computing, and civil nuclear energy—has been paused due to frustrations over non-tariff trade barriers and digital services taxes.

This development highlights the volatility of international trade agreements and the transactional nature of the current regulatory environment. To understand the full scope of the cooperation and specific provisions that are now at risk, I encourage stakeholders to review the details of the of the Memorandum of Understanding regarding the “Tech Prosperity Deal” click here.

The suspension places pledged investment from major tech players on ice and creates significant headwinds for innovation hubs in both nations. For stakeholders, this is a stark reminder that policy and prosperity are inextricably linked.

At Lanton Law and Lanton Strategies, we specialize in helping Transatlantic organizations navigate these complex government affairs and legal challenges. When the geopolitical landscape shifts, your strategy must adapt immediately.

Don't let diplomatic friction stall your innovation pipeline. Contact us today for strategic consulting on how this suspension impacts your business. Let’s discuss how we can help you pivot and thrive despite these headwinds.

What Will Happen to Biosimilars in the USMCA Agreement in 2020?

Back in August I started an analysis of how biosimilars will be impacted in the new United States-Mexico-Canada Agreement (USMCA). To refresh, in a follow up on a 2016 campaign promise to renegotiate the North American Free Trade Agreement (NAFTA), the Administration has been engaging Mexico and Canada in an effort to create and ratify the USMCA. 

One of the major points of contention in the negotiation centered on the exclusivity period of biologics. Biosimilar manufacturers raised concerns about the fact that the USMCA would award biologic manufacturers 10 years of market exclusivity. 

Fast forward to December 19, 2019 when the U.S. House of Representatives approved the USMCA with a bipartisan vote of 385-41. When it comes to biologics, the status quo remains as the exclusivity period continues to be 12 years. A provision that would have guaranteed 10 years of market exclusivity for biologic drugs was stripped out of a deal between Congress and the Administration. 

Senate Majority Leader McConnell (R-KY) stated that the U.S. Senate would consider the measure in early 2020. The reason for the delay according to the Senator is due to the looming impeachment trial for President Trump. Stay tuned for developments.

If your organization intends to either start or increase your utilization of biologic/biosimilar products or you are interested in understanding how to invest in these emerging products, contact us today.